One point worth mentioning is that when our founding fathers spoke about the right to bear arms, the "arms" they were talking about were Muskets. A typical musket firing at a single man-sized target was only accurate to about 40 to 50 yds using the ammunition of the day.
To prepare to fire you had to
Place gun in left hand to load position. Get the cartridge and tear cartridge with your two front teeth. Pour contents of cartridge into the barrel, including the bullet which you should push down with your finger. Draw rammer for use, then ram cartridge into the base of the barrel. Take ram rod out of the barrel and return to its proper location. Prime the cap to ignite the gunpowder inside then shoulder the Musket aim and fire.
Needless to say there were No mass shootings by an individual using a Musket.
Your diagnosis is a cranio-rectal inversion. An extension of the patent of Imetelstat is absolutely, undeniably a good thing for Geron and investors. In terms of any future buyout of Geron by J&J or whoever 8 more protected years for Imetestat is a Very positive value proposition. I bet if a search was done on your posts we could find disparaging posts about the short time the original patent to 2024 and how Chippy was responsible for that.
The fact that you can never see any good in anything Geron management acheives is remarkable and revealing. Sure, two sides of a viepoint are valuable but really, every day, all the time negative, sarcastic, condescending, unrelenting 22,000 + posts that many consider useless!! It seems you are so consumed with anger and hatred that one can only feel bad for you. Never-the-less my best to you and hopefully one day you can let this all consuming negativity/hatred go.
Don, Nah I totally disagree. Other companies with out any other drug in their pipeline obtaining an FDA approval for their first have seen their PPS significantly rise. The license with J&J is greatly positive in that the infrastructure is already in place to manufacture and distribute Imetelstat. Sales relations are already in Place, relations with MDs are already in Place, Pharmacy connections are already in Place, and the financial power to do all the above is solid and stable.
If Geron had to do all the above, then yes maybe the market could question if Geron management had the talent to not only invent the drug and get it through a clinical trial but to Market and Distribute it and or the funds to get that done.
J&J's world wide Infrastructure insures fast and efficient marketing and distribution of Imetelstat. Thus, any delay between IMET FDA approval and PPS is extremely unlikely.
The fact that the 24/7 nay sayers here, like Black M are now trying to downplay FDA approval makes me suspect that the short contingent is trying to get in their last hurrah. Times they are a changing at Geron and those that cling to Geron's past performance will be swept aside.
Donny what would make you think that with a J&J backed and licensed drug, Geron would not go up after FDA approval? That just doesn't make any sense even considering your global pessimistic posts here.
The cold hard reason for a low PPS is there are "No" drugs on the market at this time. If you don't have the patience or the fortitude to wait for the results of the Phase II/III clinical trials then leave, put your money somewhere else.
Mruyog, I seem to recall that the complete manufacturing of IMET and distribution is already taken over by Janssen and that Geron is only advising on the clinical trial process.
Thank you for this information.